한글목차

이 보고서는 파킨슨병 치료에 대한 조사 분석과 KOL과의 인터뷰를 통해 얻은 인사이트를 바탕으로 기존 치료제와 파이프라인 치료제의 효과, 과제 및 가능성에 초점을 맞춰 파킨슨병의 현재와 미래 치료 상황에 대한 자세한 정보를 제공합니다.

기업

목차

주요 요약

현재와 향후 치료 알고리즘

조사 목적

파킨슨병의 현재 치료 관행과 미충족 수요

파킨슨병 치료의 새로운 방향성

승인된 치료법

• 도파민 작용제
• 고정용량 배합제(FDC)
• MAO-B 억제제
• COMT 억제제
• 기타 약제

파이프라인 치료법

• 도파민 작용제
  • Aplindore(DAB 452, Seelos Therapeutics)
  • Tavapadon(AbbVie/Cerevel Therapeutics)
• FDC 치료법
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612(levodopa + carbidopa subcutaneous infusion, NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001(pramipexole + rasagiline, Pharma Two B)
• 기타 작용기서
  • Nabilone FDT(AOP Orphan Pharmaceuticals)
  • Mesdopetam(Integrative Research Laboratories)
  • Buntanetap(R-phenserine/Posiphen, Annovis Bio)
• 조기 단계 의약품 후보
  • Alpha-synuclein inhibitors
  • UCB0599(UCB)
  • PRX002(prasinezumab, Roche)
  • ENT-01(kenterin, Enterin)
  • ION464(Ionis Pharma/Biogen)
  • Radotinib(Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• 기타 작용기서/파이프라인 후보

향후 치료 패러다임

부록

영문목차

Based on insights from interviews with key opinion leaders, this report provides an in depth look into the current and future treatment landscape for Parkinson's Disease, focusing on the efficacy, challenges, and potential of existing and pipeline therapies. Gain a comprehensive understanding of treatment algorithms, unmet needs, and the evolving therapeutic strategies, including the role of levodopa, emerging therapies like GLP-1 agonists, and innovative brain infusion techniques.

Key questions answered:

• What treatments currently form the backbone of Parkinson's Disease therapy?
• What are the advantages and disadvantages of these treatments?
• What are the current unmet needs and challenges in treating Parkinson's Disease?
• Which products are currently in the development pipeline, and what impact are they expected to have on treatment pathways?
• Do any of the current pipeline therapies address unmet treatment needs?
• How is the Parkinson's Disease treatment landscape expected to evolve over the next three to five years?

Key brands covered in this report:

• Alpha-synuclein inhibitors (e.g. cinpanemab, ENT-01, ION464, prasinezumab, UCB0599)
• Buntanetap ((+)(3aR)phenserine)
• Cell/gene therapies and various other early-stage MOAs
• Comtan (entacapone)
• DNL151
• Dostinex (cabergoline)
• Duopa (levodopa/carbidopa intraduodenal)
• IPX203 (carbidopa/levodopa)
• Mesdopetam
• Ongentys (opicapone)
• P2B-001 (pramipexole/rasagiline)
• PRODUODOPA/VYALEV (foscarbidopa/foslevadopa)
• Repurposed drugs (e.g. nilotinib, GLP-1 agonists (exenatide sustained-release, liraglutide, lixisenatide NLY01), etc.)
• Requip franchise (ropinirole/ER)
• Rytary (levodopa/carbidopa ER)
• Stalevo (levodopa/carbidopa/entacapone)

Companies:

Table of Contents

Executive summary

• This report is based on the leading insights from interviews with six key opinion leaders (KOLs) from the USA and six from Europe. FirstWord's research and analysis for Therapy Trends KOL Insight: Parkinson's Disease identified the following major findings:

Current and future treatment algorithm

Research objectives

Current treatment practice and unmet needs in Parkinson's disease

• Key insights summary
  • First-line treatment for PD is usually either levodopa, a dopamine agonist or a MAO-B inhibitor, depending on age, activity, severity of symptoms and formulation convenience

New directions in Parkinson's disease therapy

• Key insights summary
  • Promising new directions in PD treatment include subcutaneous levodopa, LRRK2 targeting, repurposed GLP-1 agonists and brain infusion of dopamine

Approved therapies

• Dopamine agonists
  • Key insights summary
• Fixed-dose combination (FDC) agents
  • Key insights summary
• MAO-B inhibitors
  • Key insights summary
• COMT inhibitors
  • Key insights summary
• Other agents
  • Key insights summary

Pipeline therapies

• Dopamine agonists
  • Aplindore (DAB 452; Seelos Therapeutics)
  • Tavapadon (AbbVie/Cerevel Therapeutics)
• FDC therapies
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001 (pramipexole + rasagiline; Pharma Two B)
• Other modes of action
  • Nabilone FDT (AOP Orphan Pharmaceuticals)
  • Mesdopetam (Integrative Research Laboratories)
  • Buntanetap (R-phenserine/Posiphen; Annovis Bio)
• Early-phase drug candidates
  • Alpha-synuclein inhibitors
  • UCB0599 (UCB)
  • PRX002 (prasinezumab; Roche)
  • ENT-01 (kenterin; Enterin)
  • ION464 (Ionis Pharma/Biogen)
  • Radotinib (Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• Other mechanisms of action/pipeline candidates
  • Key insights summary

Future treatment paradigm

• Key insights summary
  • Disease modification remains elusive in PD, but the next five years should see better and earlier symptomatic treatment, together with more attention to non-motor symptoms

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe